^
    No biomarker
    Adrenal Cortex Carcinoma
    mitotane
    Sensitive
    :
    A1
    No biomarker
    Adrenal Cortex Carcinoma
    cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    cisplatin
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    cisplatin + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    carboplatin + etoposide IV + mitotane
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    carboplatin + doxorubicin hydrochloride + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    carboplatin + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    cisplatin + etoposide IV + mitotane
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    cisplatin + doxorubicin hydrochloride + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    streptozocin
    Sensitive
    :
    A2
    No biomarker
    Adrenal Cortex Carcinoma
    mitotane + streptozocin
    Sensitive
    :
    A2
    MSI-H/dMMR
    Adrenal Cortex Carcinoma
    pembrolizumab
    Sensitive
    :
    C1
    RRM1 underexpression
    Adrenal Cortex Carcinoma
    mitotane
    Sensitive
    :
    C3
    TMB-L
    Adrenal Cortex Carcinoma
    mitotane
    Sensitive
    :
    C3
    MGMT underexpression
    Pituitary Gland Carcinoma
    temozolomide
    Sensitive
    :
    C3
    MSH2 mutation
    Adrenal Cortex Carcinoma
    pembrolizumab
    Sensitive
    :
    C4
    SDHB mutation
    Pituitary Gland Carcinoma
    temozolomide
    Sensitive
    :
    C4
    MSH2 mutation + MSH6 mutation
    Pituitary Gland Carcinoma
    pembrolizumab
    Sensitive
    :
    C4
    TMB-L + PD-L1 underexpression
    Pituitary Gland Carcinoma
    nivolumab + ipilimumab
    Sensitive
    :
    C4
    STK11 mutation
    Pituitary Gland Carcinoma
    temozolomide + capecitabine
    Resistant
    :
    C4
    STK11 mutation
    Pituitary Gland Carcinoma
    everolimus
    Sensitive
    :
    C4
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES